The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.

PHASE4TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 12, 2017

Primary Completion Date

March 20, 2020

Study Completion Date

March 20, 2020

Conditions

Diabetes Mellitus, Type 2Kidney Function Tests

Interventions

DRUG

Dapagliflozin

The study consists of a 2-week, open label, dapagliflozin (10mg) treatment period.

Trial Locations (4)

Research Site, Stockholm

Research Site, Örebro

Research Site, Almelo

Research Site, Amsterdam